Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients (Q24202128)

title

Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464614&resulttype=core&format=json

13 May 2020

0 references

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464614&resulttype=core&format=json

13 May 2020

author name string

Dimitrios Lathyris

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464614&resulttype=core&format=json

13 May 2020

Arturo J Martí-Carvajal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464614&resulttype=core&format=json

13 May 2020

Ivan Solà

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464614&resulttype=core&format=json

13 May 2020

Andrés Felipe Cardona

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464614&resulttype=core&format=json

Cochrane Database of Systematic Reviews

13 May 2020

publication date

12 December 2012

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464614&resulttype=core&format=json

13 May 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464614&resulttype=core&format=json

13 May 2020

page(s)

CD004388

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464614&resulttype=core&format=json

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Recombinant Human Activated Protein C for Adults with Septic Shock. A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Drotrecogin alfa (activated) treatment of older patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Severe protein C deficiency predicts early death in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Drotrecogin alfa (activated) in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Drotrecogin alfa (activated) in adults with septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Recombinant human activated protein C for use in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Activated protein C for the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Recombinant human activated protein C for severe sepsis in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Hemodynamic effects of recombinant human activated protein C in patients with septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Epidemiology of sepsis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Novel potential therapies for septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Racial variation in the incidence, care, and outcomes of severe sepsis: analysis of population, patient, and hospital characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

21 January 2018

Antibiotics in sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Sepsis: time to reconsider the concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Protein C and acute inflammation: a clinical and biological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Molecular biology of inflammation and sepsis: a primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Non-antibiotic strategies for sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Diagnosis of infection in sepsis: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

The puzzle of sepsis: fitting the pieces of the inflammatory response with treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

21 January 2018

New therapies for sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Critical advances in septicemia and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Evaluating non-randomised intervention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Inflammation and the activated protein C anticoagulant pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Protein C levels as a prognostic indicator of outcome in sepsis and related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Historical perspective of the word "sepsis".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Pharmacological treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Incidence and impact of organ dysfunctions associated with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

GRADE guidelines: 2. Framing the question and deciding on important outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

GRADE guidelines: 9. Rating up the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

GRADE guidelines: 8. Rating the quality of evidence--indirectness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

GRADE guidelines: 7. Rating the quality of evidence--inconsistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

GRADE guidelines 6. Rating the quality of evidence—imprecision

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

GRADE guidelines: 5. Rating the quality of evidence--publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

New and emerging therapies for sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Treatment of sepsis with activated protein C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Immunotherapy for sepsis--a new approach against an ancient foe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

New insight in LPS antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Meta-research: The art of getting it wrong

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

[Epidemiology and costs of severe sepsis in Madrid. A hospital discharge study].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Emerging drugs in sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

The coagulant response in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Implications of pharmaceutical industry funding on clinical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Protein C in critical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Source control in the management of severe sepsis and septic shock: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Sepsis: rethinking the approach to clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Experimental therapeutic strategies for severe sepsis: mediators and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Is there a treatment for sepsis other than antibiotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Early goal-directed therapy: an evidence-based review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Pathogenesis-oriented targets for adjunctive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Harmful molecular mechanisms in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Controversies in the treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Corticosteroids in severe pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Effect of various genetic polymorphisms on the incidence and outcome of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Pharmaceutical company funding and its consequences: a qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

The immunology of sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Reducing mortality in sepsis: new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Evidence-based medicine in the ICU: important advances and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

The apoptotic pathway as a therapeutic target in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Adjunctive therapies for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Activated protein C versus protein C in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Antibiotics for treating osteomyelitis in people with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Human recombinant activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Human recombinant activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Human recombinant activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Human recombinant activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB6

Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Adverse events and clinical outcome associated with drotrecogin alfa-activated: a single-center experience of 498 patients over 8 years

1 reference

12 December 2020

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)

1 reference

12 December 2020

Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China

1 reference

12 December 2020

Appraisal of four novel approaches to the prevention and treatment of sepsis.

1 reference

12 December 2020

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis

1 reference

12 December 2020

An update on activated protein C (xigris) in the management of sepsis

1 reference

12 December 2020

Therapeutic potential of HMGB1-targeting agents in sepsis

1 reference

12 December 2020

[Potential benefits of non-anti-infective treatments of septic shock: a critical analysis of literature]

1 reference

12 December 2020

Treatment of septic shock and use of drotrecogin alfa (activated) in children

1 reference

12 December 2020

The epidemiology of, and risk factors for, mortality from severe sepsis and septic shock in a tertiary-care university hospital setting

1 reference

12 December 2020

ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation

1 reference

12 December 2020

Drug for severe sepsis is withdrawn from market, fails to reduce mortality

1 reference

12 December 2020

Unblinding plan of PROWESS-SHOCK trial

1 reference

12 December 2020

Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis

1 reference

12 December 2020

1 reference

12 December 2020

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial

1 reference

12 December 2020

How pharmaceutical industry funding affects trial outcomes: causal structures and responses

1 reference

12 December 2020

Prevalence of serious bleeding events and intracranial hemorrhage in patients receiving activated protein C: a systematic review and meta-analysis

1 reference

12 December 2020

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety

1 reference

12 December 2020

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

1 reference

12 December 2020

Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis

1 reference

12 December 2020

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

1 reference

12 December 2020

Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals

1 reference

12 December 2020

Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without Streptococcus pneumoniae

1 reference

12 December 2020

Pathophysiology of sepsis

1 reference

12 December 2020

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

1 reference

12 December 2020

Recombinant human activated protein C in severe sepsis

1 reference

12 December 2020

1 reference

12 December 2020

Seasonal variation in the epidemiology of sepsis

1 reference

12 December 2020

Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis

1 reference

12 December 2020

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis

1 reference

12 December 2020

Statistical analysis plan of PROWESS SHOCK study.

1 reference

12 December 2020

[Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis]

1 reference

12 December 2020

The roles of funding source, clinical trial outcome, and quality of reporting in orthopedic surgery literature.

1 reference

12 December 2020

[Epidemiology of severe sepsis]

1 reference

12 December 2020

Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis

1 reference

12 December 2020

10.1002/14651858.CD004388.PUB6

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

2273072

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464614&resulttype=core&format=json

13 May 2020

2273072

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6464614&resulttype=core&format=json

13 May 2020

PubMed publication ID

23235609

2 references

Consolidated OpenCitations Corpus – April 2017

2273072